FDA Wants Your Pain Points: New Guide for Patient-Centric Drug Tools
Published Date: 11/18/2025
Notice
Summary
The FDA just released new guidance to help drug makers and researchers better include patient experiences when creating or updating tools that measure how well treatments work. This means patients, caregivers, and industry folks can share real-world info to make drug development more patient-friendly. The guidance is effective now and aims to speed up smarter, more meaningful medical product decisions without extra costs.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Patients Can Submit Experience Data
You (patients, caregivers, researchers, and medical product developers) can collect and submit patient experience and caregiver information to the FDA to be used for medical product development and regulatory decision-making. The final guidance, announced November 18, 2025, explains how to select, develop, or modify clinical outcome assessments that measure outcomes important to patients.
Guidance Adds No New Paperwork
The guidance contains no new collection of information under the Paperwork Reduction Act and instead refers to previously approved OMB collections, including control numbers such as 0910-0078, 0910-0332, 0910-0231, 0910-0120, 0910-0844, 0910-0756, 0910-0449, 0910-0001, 0910-0338, 0910-0014, 0910-0130, 0910-0303, and 0910-0429. That means the guidance itself does not create new reporting requirements for regulated parties.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-12239 — Agency Information Collection Activities; Proposed Collection; Comment Request; Extralabel Drug Use in Animals
The FDA wants your thoughts on how they collect info about using drugs in animals in ways not originally approved (called extralabel use). This affects vets, farmers, and animal drug makers who report this info. You’ve got until August 17, 2026, to share your comments—no cost changes, just making sure the paperwork is clear and easy.
2026-12236 — SpecGx LLC; Withdrawal of Approval of Abbreviated New Drug Application for Methylphenidate Hydrochloride Extended-Release Tablets, 27 Milligrams, 36 Milligrams, and 54 Milligrams
SpecGx LLC has asked the FDA to withdraw its approval for three strengths (27 mg, 36 mg, and 54 mg) of its methylphenidate extended-release tablets, effective June 18, 2026. This means these specific versions of the medicine will no longer be allowed on the market. Patients and pharmacies using these doses should look for alternatives, but no extra costs or penalties are mentioned.
2026-12235 — Advisory Committee; Science Board to the Food and Drug Administration; Renewal
The FDA is renewing its Science Board for two more years, keeping expert advice flowing to help ensure safe and effective drugs and products. This renewal affects scientists and public health folks who guide the FDA’s big decisions, with the new term lasting until June 26, 2028. No extra costs or delays are expected—just more smart brains working for your health!
2026-12245 — Authorization of Emergency Use for Two Animal Drugs for the Prevention and Treatment of New World Screwworm; Availability
The FDA just gave the green light for two new animal drugs to fight the nasty New World screwworm, a bug that harms cattle, horses, pigs, and even exotic animals. These emergency approvals started in April 2026 to help protect U.S. livestock and wildlife quickly. Farmers, vets, and animal lovers can now use these treatments to stop infestations and keep animals safe without delay.
2026-12238 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements
The FDA is asking for public feedback by July 20, 2026, on their rules that keep dietary supplements safe and made right. These rules affect companies that make, package, label, or store supplements, helping ensure products are high quality without adding extra costs. This review keeps the safety standards up-to-date and clear for everyone involved.
2026-12237 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Current Good Manufacturing Practice Regulations for Type A Medicated Articles and Medicated Feeds
The FDA is updating how companies that make special animal medicines and feeds keep their records and follow quality rules. This affects manufacturers of Type A medicated articles and medicated feeds, helping ensure safe and reliable products for animals. Comments on these changes are open until July 20, 2026, and the updates aim to keep things clear without adding extra costs.
Previous / Next Documents
Previous: 2025-20152 — Notice of OFAC Sanctions Actions
The U.S. Treasury’s OFAC just blocked the property of two people from Colombia linked to illegal drug activities. From October 24, 2025, Americans can’t do business with them, freezing their assets under U.S. law. This move aims to cut off money and resources fueling the global drug trade.
Next: 2025-20155 — Lightweight Thermal Paper From the People's Republic of China: Final Results of the Expedited Third Sunset Review of the Countervailing Duty Order
The U.S. Department of Commerce decided to keep extra taxes on lightweight thermal paper imported from China because stopping them could let unfair government help continue. This affects Chinese exporters and U.S. companies like Domtar that make similar paper here. These duties stay in place starting November 18, 2025, helping protect American businesses from unfair competition.